TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy
TAIPEI, , Nov. 15, 2018 /PRNewswire/ -- TWi Biotechnology, Inc. (TWiB, 6610.TWO), a clinical stage drug development company targeting rare, chronic and inflammatory diseases, announced today that it has completed patient enrollment in its Phase 2 clinical trial (Study code: AC-201CR-HA-001) of A...
2018-11-15 17:16
1659
TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
TAIPEI, , Feb. 26, 2018 /PRNewswire/ -- TWi Biotechnology, Inc. ("TWi Biotech",TWO: 6610), a clinical stage biotechnology company focused on developing inhibitors of inflammasomes, today announced that it has received approval from the Taiwan Food and Drug Administration (TFDA) to proceed a phase...
2018-02-26 16:58
1147
